Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0296 • ACR Convergence 2022
Characteristics and Treatment-selection in Patients with Rheumatoid Arthritis and with Inadequate Response to Janus Kinase Inhibitors
Yusuke Miyazaki¹, Shingo Nakayamada², Satoshi Kubo³, Koshiro Sonomoto², Yoshino Inoue², shunsuke fukuyo², Kentaro Hanami² and Yoshiya Tanaka⁴, ¹The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kiakyusyu Fukuoka, Japan, ²First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ³Department of Advanced Targeted Therapies, University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁴University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan
Background/Purpose: Janus kinase inhibitors (JAKinib) are effective in patients with rheumatoid arthritis (RA); however, some patients show an inadequate response to JAKinibs (JAKinib-IR). This study…
Abstract Number: 0314 • ACR Convergence 2022
Olokizumab Improved Patient Reported Outcomes in TNF Incomplete Responder (TNF-IR) Rheumatoid Arthritis Patients: Results from the Phase III Randomized Controlled Trial
Vibeke Strand¹, Evgeny Nasonov², Tatiana Lisitsyna², Alexander Lila², Sofia Kuzkina³, Mikhail Samsonov⁴ and Eugen Feist⁵, ¹Stanford University School of Medicine, Stanford, CA, ²V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ³R-Pharm, Moscow, Russia, ⁴R-Pharm JSC, Moscow, Russia, ⁵Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany
Background/Purpose: Olokizumab (OKZ) is an interleukin-6-inhibitor for treatment of rheumatoid arthritis (RA). In these analyses we present patient reported outcomes (PROs) reported by TNF-IR patients…
Abstract Number: 0549 • ACR Convergence 2022
Efficacy and Safety of the SARS-CoV-2 Vaccine in Patients with Rheumatoid Arthritis
Esther Vicente-Rabaneda¹, María Torres², Miren Uriarte³, Patricia Quiroga-Colina³, Ainhoa Gutiérrez⁴, Ana Triguero⁵, Francisco Gutiérrez³, Noelia García³, Ana Romero-Robles³, Laura Cardeñoso⁴ and Santos Castañeda¹, ¹Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ²Medical student, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁴Division of Microbiology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Hospital Universitario La Princesa, Madrid, Spain
Background/Purpose: To describe the efficacy and safety of the SARS-CoV-2 vaccine in a series of patients with rheumatoid arthritis (RA).Methods: Retrospective observational study of RA…
Abstract Number: 0594 • ACR Convergence 2022
Identification of Peptidylglycine Alpha-Amidating Monooxygenase as a Regulator of Tissue Damage Mediated by Rheumatoid Arthritis Synovial Fibroblasts
Kevin Sheridan¹, Emma Dorris¹, Christopher Buckley² and Anthony Wilson¹, ¹University College Dublin, Dublin, Ireland, ²University of Oxford, Oxford, United Kingdom
Background/Purpose: The minor C allele variant of rs26232 SNP, located within the first intron of the Macrophage Immunometabolism regulator (MACIR) gene, is associated with both…
Abstract Number: 0611 • ACR Convergence 2022
Proteomics Reveals Dysregulated Molecular Mechanisms of Cell Death in Neutrophils in Rheumatoid Arthritis
Jennifer Amsler¹, Constance Beaudouin², Morgane LeGall³, Géraldine Falgarone⁴, François Rannou⁵, Léa Tourneur³ and Véronique Witko-Sarsat³, ¹Institute Cochin, Schoenenwerd, Switzerland, ²Hôpital Privé de Provence, Aix-en-Provence, France, ³Institute Cochin, Paris, France, ⁴Hôpital Avicenne, Paris, France, ⁵Hôpital Cochin, Paris, France
Background/Purpose: Favoring apoptosis of neutrophils infiltrating the joints of patients suffering from rheumatoid arthritis (RA) and perpetuating inflammation has recently been discussed as an alternative…
Abstract Number: 0628 • ACR Convergence 2022
A Positive-feedback Model for the Contribution of Virus-Specific T Cells to the Development of Rheumatoid Arthritis
Hendrik Nel¹, Pascale Wehr², Christopher Andoniou³, Iona Schuster³, Stephanie Gras⁴, Helen McGuire⁵, Helen Weedon⁶, Annabelle Small⁷, Katie Lowe⁷, Mariapia Degli-Esposti³, Mihir Wechalekar⁸ and Ranjeny Thomas⁹, ¹University of Queensland, Brisbane, Australia, Woolloongabba, Australia, ²University of Queensland Diamantina Institute, Brisbane, Australia, ³Infection and Immunity Program and Department of Microbiology, Biomedicine Discovery Institute, Monash, Australia, ⁴Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia, ⁵The University of Sydney, Charles Perkins Centre, Camperdown, Australia, ⁶Flinders University of South Australia, Bedford Park, Australia, ⁷Flinders University, Adelaide, Australia, ⁸Flinders Medical Centre, Bedford Park, Australia, ⁹University of Queensland, Brisbane, Australia
Background/Purpose: Rheumatoid Arthritis (RA) is associated with specific HLA-DR genotypes with an emphasis on the role of CD4+ effector-memory T cells (Tem) in disease pathogenesis.…
Abstract Number: 0763 • ACR Convergence 2022
Immunogenicity Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis
Vibeke Strand¹, Shaun Bender² and Dorothy McCabe³, ¹Stanford University School of Medicine, Stanford, CA, ²Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, ³Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT
Background/Purpose: The VOLTAIRE trials program compared the safety, efficacy, and immunogenicity of biosimilar BI 695501 with adalimumab reference product (RP) for indications including moderate-severely active…
Abstract Number: 0884 • ACR Convergence 2022
Serum Calprotectin Can Differentiate Between Sustained Remission and Low Disease Activity States in Rheumatoid Arthritis
Margaret Ma¹, Fowzia Ibrahim², David Scott² and Andrew Cope³, ¹National University Hospital, Singapore, Singapore, ²King's College London, London, United Kingdom, ³King's College London, Surrey, United Kingdom
Background/Purpose: Reliable objective assessment of remission is important for the optimal management of rheumatoid arthritis (RA) patients. Calprotectin is a heterocomplex of the S100 proteins…
Abstract Number: 0900 • ACR Convergence 2022
Effect of Biologic Agents on Lipid Levels and Cardiovascular Risk in Rheumatoid Arthritis Patients
Dimitrios Pappas¹, Jon Giles², George Reed³, Kevin Kane⁴, Jeffrey Curtis⁵ and Joel Kremer⁶, ¹CorEvitas, LLC, Waltham, MA, ²Columbia University, New York, NY, ³The Corrona Research Foundation and University of Massachusetts, Albany, NY, ⁴University of Massachusetts, Worcester, MA, ⁵University of Alabama at Birmingham, Hoover, AL, ⁶The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: Cardiovascular (CV) risk in RA is increased due to interaction between traditional risk factors and systemic inflammation. The purpose of this analysis was to…
Abstract Number: 0916 • ACR Convergence 2022
Should RA Patients with Controlled Disease Taper Methotrexate from Targeted Therapy or Continue It? Risk Differences in Sustaining Remission from a Systematic Review and Meta-analysis
Charis Meng, Diviya Rajesh, Bridget Jivanelli, Deanna Jannat-Khah, DrPH, MSPH and Vivian Bykerk, Hospital for Special Surgery, New York, NY
Background/Purpose: Patients with RA often struggle with side effects of methotrexate (MTX). ACR guidelines conditionally recommend the tapering of MTX before tapering biologic (b)DMARDs, but…
Abstract Number: 0933 • ACR Convergence 2022
Exploratory Study of the Usefulness of TNFAIP3 Genetic Variants in Predicting Response to Methotrexate in Early Arthritis Patients
Ana Triguero¹, JUAN BALDIVIESO ACHA², Emilia Roy Vallejo³, Patricia Quiroga-Colina⁴, Irene Maria Llorente Cubas², Rosario Garcia-Vicuña⁵, amaya Puig kröger⁶ and Isidoro Gonzalez², ¹Hospital Universitario La Princesa, Madrid, Spain, ²Hospital Universitario de La Princesa, Madrid, Spain, ³Internal Medicine Department, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁶Laboratory of Immunometabolism, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: We recently described that methotrexate (MTX) could exert its immunomodulatory effect through the induction of A20 expression , a protein that negatively regulates NFkB…
Abstract Number: 1130 • ACR Convergence 2022
Identification of Novel Molecular Signatures Associated with the Therapeutic Response to DMARDs and TNFi Therapies in Rheumatoid Arthritis Patients Through High Throughput Proteomics
Carlos Pérez-Sánchez¹, Laura Muñoz-Barrera¹, Tomás Cerdó², Ismael Sánchez-Pareja², Jerusalem Calvo-Gutierrez², Rafaela Ortega-Castro¹, Montserrat Romero-Gomez², María Ángeles Aguirre-Zamorano³, María Carmen Ábalos-Aguilera⁴, Nuria Barbarroja¹, José Perez-Venegas⁵, Mª Dolores Ruiz-Montesinos⁵, Carmen Dominguez⁵, Carlos Rodriguez-Escalera⁶, Carmen Romero-Barco⁶, Antonio Fernandez-Nebro⁷, Natalia Mena Vazquez⁷, Jose Luis Marenco⁸, Julia Uceda Montañez⁸, Charo Santos⁹, Eduardo Collantes¹, Alejandro Escudero-Contreras² and Chary Lopez-Pedrera¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁴Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, ⁵Virgen Macarena University Hospital, Sevilla, Spain, ⁶Virgen de la Victoria Hospital, Málaga, Spain, ⁷Regional University Hospital of Málaga, Málaga, Spain, ⁸Virgen de Valme University Hospital, Sevilla, Spain, ⁹Virgen de Valme University Hospital, Málaga, Spain
Background/Purpose: The clinical outcome of conventional disease-modifying antirheumatic drugs (DMARDs) and TNF inhibitors (TNFi) is still unpredictable in rheumatoid arthritis (RA) patients. Thus, innovative analyses…
Abstract Number: 1241 • ACR Convergence 2022
Towards a Simplified Fluid-sensitive MRI Protocol in Small Joints of the Hand in Early Arthritis Patients: Reliability Between mDixon and Regular FSE Fat Saturation MRI-sequences
Anna M.P. Boeren¹, Ellis Niemantsverdriet², Marloes Verstappen³, Fenne Wouters⁴, Monique Reijnierse³, J.L. Bloem⁵ and Annette van der Helm-van Mil⁶, ¹Erasmus MC, Rotterdam, Rotterdam, ²LUMC, Leiden, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Leiden University Medical Centre (LUMC), Leiden, ⁵Leiden University Medical Centre (LUMC), Leiden, Netherlands, ⁶Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: MRI of small joints is, despite its sensitivity in demonstrating inflammation, hardly used in rheumatologic clinical practice. Widespread use is hampered by invasiveness, long…
Abstract Number: 1353 • ACR Convergence 2022
Dietary Practices and Beliefs of Patients with Rheumatic Diseases and Relationship with Symptoms: Results of a Multicenter Cross-sectional Study
Domitille RENARD¹, Sophie Tuffet², Philippe Dieude³, Pascal Claudepierre⁴, Laure Gossec⁵, Bruno Fautrel⁶, Anna Molto⁷, Corinne MIceli⁸, Pascal Richette⁹, Emmanuel Maheu¹⁰, Claire Carette¹¹, Sebastien Czernichow¹¹, Chloe JAMAKORZYAN¹², alexandra Rousseau², Francis Berenbaum¹³, Catherine Beauvais¹⁴ and Jérémie SELLAM¹⁵, ¹Sorbonne University Paris- Sant Antoine Hospital, Paris, France, ²Saint Antoine hospital, Paris, Ile-de-France, France, ³Université Paris Cité, Paris, France, ⁴Paris Est Creteil University, Creteil, France, ⁵Sorbonne Université, Paris, France, ⁶Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ⁷Rheumatology Department, Cochin Hospital, APHP, Paris, France, ⁸APHP, Paris, France, ⁹Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ¹⁰Hôpital Paris Saint Antoine, Moirans, Auvergne-Rhône-Alpes, France, ¹¹Hôpital Européen Georges Pompidou, Paris, France, ¹²Hopital Begin, Saint-Mandé, France, ¹³Sorbonne University - Saint-Antoine hospital, Paris, France, ¹⁴Saint Antoine hospital, Paris, France, ¹⁵Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France
Background/Purpose: Diet is a subject of questioning and beliefs among patients with rheumatic diseases. They are inclined to change their eating habits and sometimes follow…
Abstract Number: 1400 • ACR Convergence 2022
Machine Learning Identifies Molecular Phenotypes That Predict Incident Cardiovascular Disease in Patients with Rheumatoid Arthritis
Tate Johnson¹, Rebekah Gundry², Merry Lindsey², Punyasha Roul³, Yangyuna Yang², Joshua Baker⁴, Brian Sauer⁵, Grant Cannon⁶, Geoffrey Thiele², Ted Mikuls⁷ and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Retired, Salt Lake City, UT, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cardiovascular disease (CVD) remains the leading cause of death in patients with rheumatoid arthritis (RA). General population CVD risk calculators underestimate risk in RA,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.